Form 4: Y-mAbs Therapeutics Director Mary Tagliaferri Reports Stock and Option Awards

Director Mary Tagliaferri received restricted stock units and stock options from Y-mAbs Therapeutics, according to a Form 4 filing.

Summary

• Mary Tagliaferri, a director of Y-mAbs Therapeutics, reported the acquisition of 4,660 restricted stock units (RSUs) and 27,900 stock options on March 12, 2024.
• The RSUs were granted as part of the 2018 Equity Incentive Plan and represent a contingent right to receive one share of Common Stock per RSU.
• The RSUs vest in equal quarterly installments over three years, starting three months after March 12, 2024, contingent upon continued service.
• The stock options, also granted under the 2018 Equity Incentive Plan, have an exercise price of $16.09.
• These options vest in equal monthly installments over three years, beginning one month after March 12, 2024, also contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral event with a slightly positive implication for long-term commitment.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company over the next three years.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Y-mAbs Therapeutics' stock.
• If the director ceases to provide service to the company, the unvested RSUs and stock options will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Grants of stock options and restricted stock units are common practice for compensating and incentivizing directors and key employees in the biotechnology industry.

Comparison to Industry Standards

• Equity grants to non-employee directors are a standard practice in publicly traded companies, particularly in the biotech sector, to align their interests with shareholders.
• The vesting schedules (quarterly for RSUs and monthly for options) are fairly typical, encouraging long-term commitment.
• Comparable companies like BioNTech or Moderna also utilize equity-based compensation for their board members.

Stakeholder Impact

• The grants align the director's interests with shareholders, potentially leading to better corporate governance and decision-making.
• Employees may view this as a positive sign of commitment from the board.

Key Dates